Additionally, the 36-month beta value for MRNA is 1.62. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for MRNA is 336.20M and currently, short sellers hold a 6.58% ratio of that float. The average trading volume of MRNA on March 27, 2024 was 4.45M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
MRNA) stock’s latest price update
The stock of Moderna Inc (NASDAQ: MRNA) has decreased by -2.69 when compared to last closing price of 110.38. Despite this, the company has experienced a 2.19% gain in its stock price over the last five trading sessions. Investopedia reported 2024-03-26 that Moderna Inc. (MRNA) on Tuesday reported “positive interim results” from a late-stage study of what it calls the “next-generation COVID-19 vaccine.”
MRNA’s Market Performance
Moderna Inc (MRNA) has experienced a 2.19% rise in stock performance for the past week, with a 14.24% rise in the past month, and a 13.19% rise in the past quarter. The volatility ratio for the week is 3.71%, and the volatility levels for the past 30 days are at 4.52% for MRNA. The simple moving average for the past 20 days is 5.21% for MRNA’s stock, with a 6.73% simple moving average for the past 200 days.
Analysts’ Opinion of MRNA
Many brokerage firms have already submitted their reports for MRNA stocks, with HSBC Securities repeating the rating for MRNA by listing it as a “Reduce.” The predicted price for MRNA in the upcoming period, according to HSBC Securities is $86 based on the research report published on February 26, 2024 of the current year 2024.
Oppenheimer, on the other hand, stated in their research note that they expect to see MRNA reach a price target of $142. The rating they have provided for MRNA stocks is “Outperform” according to the report published on January 02nd, 2024.
Canaccord Genuity gave a rating of “Hold” to MRNA, setting the target price at $82 in the report published on November 29th of the previous year.
MRNA Trading at 8.68% from the 50-Day Moving Average
After a stumble in the market that brought MRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.20% of loss for the given period.
Volatility was left at 4.52%, however, over the last 30 days, the volatility rate increased by 3.71%, as shares surge +11.65% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.38% upper at present.
During the last 5 trading sessions, MRNA rose by +2.19%, which changed the moving average for the period of 200-days by -14.03% in comparison to the 20-day moving average, which settled at $102.65. In addition, Moderna Inc saw 8.00% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRNA starting from AFEYAN NOUBAR, who sale 15,000 shares at the price of $102.39 back on Mar 20 ’24. After this action, AFEYAN NOUBAR now owns 2,116,931 shares of Moderna Inc, valued at $1,535,820 using the latest closing price.
Hoge Stephen, the President of Moderna Inc, sale 15,000 shares at $103.17 during a trade that took place back on Mar 15 ’24, which means that Hoge Stephen is holding 1,501,241 shares at $1,547,550 based on the most recent closing price.
Stock Fundamentals for MRNA
Current profitability levels for the company are sitting at:
- -0.62 for the present operating margin
- 0.31 for the gross margin
The net margin for Moderna Inc stands at -0.69. The total capital return value is set at -0.28. Equity return is now at value -28.59, with -21.18 for asset returns.
Based on Moderna Inc (MRNA), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -2.51. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is 132.47.
Currently, EBITDA for the company is -3.21 billion with net debt to EBITDA at 0.47. When we switch over and look at the enterprise to sales, we see a ratio of 5.76. The receivables turnover for the company is 6.34for trailing twelve months and the total asset turnover is 0.37. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.42.
Conclusion
In conclusion, Moderna Inc (MRNA) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
